GeoPolitics Pulse

The Heartbeat of World events

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

by ·

TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc.Read More

Related posts:

  1. Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
  2. Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
  3. Update on regulatory review of lecanemab for treatment of early Alzheimer’s disease in the …
  4. EU Regulatory Review Adopts Negative Opinion of Lecanemab as Treatment for Alzheimer Disease
  5. Eisai Gets Positive Opinion From CHMP In European Union For Lecanemab In Early … – Nasdaq